Mendel Money Management Acquires Shares of 3,005 Illumina, Inc. (NASDAQ:ILMN)

Mendel Money Management acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 3,005 shares of the life sciences company's stock, valued at approximately $402,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. WCM Investment Management LLC boosted its stake in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after acquiring an additional 867,673 shares in the last quarter. ARK Investment Management LLC purchased a new position in shares of Illumina during the fourth quarter valued at approximately $91,714,000. Janus Henderson Group PLC boosted its position in shares of Illumina by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after purchasing an additional 625,245 shares in the last quarter. Nikko Asset Management Americas Inc. purchased a new stake in shares of Illumina in the 4th quarter worth approximately $65,813,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in Illumina by 116.9% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company's stock valued at $115,663,000 after buying an additional 466,519 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ILMN shares. Robert W. Baird dropped their target price on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. Piper Sandler upped their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Royal Bank of Canada cut their price objective on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 12th. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Finally, Morgan Stanley cut their price target on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $140.90.

Remove Ads

Illumina Price Performance

Shares of ILMN stock traded down $2.28 during mid-day trading on Friday, hitting $80.00. The company had a trading volume of 1,526,373 shares, compared to its average volume of 2,212,008. The company has a market capitalization of $12.67 billion, a P/E ratio of -10.42, a P/E/G ratio of 1.60 and a beta of 1.17. The stock's 50 day moving average price is $102.80 and its 200-day moving average price is $126.81. Illumina, Inc. has a 52-week low of $79.30 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities research analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.